Financial Performance - The company's operating revenue for Q1 2019 was ¥717,015,649.78, representing a 2.43% increase compared to ¥699,991,074.72 in the same period last year[3]. - The net profit attributable to shareholders for Q1 2019 was ¥211,005,149.07, up by 2.44% from ¥205,986,366.58 year-on-year[3]. - The company's operating profit for Q1 2019 was CNY 252.59 million, an increase from CNY 246.12 million in the same period last year, representing a growth of approximately 2.0%[22]. - The total profit for Q1 2019 was CNY 251.03 million, compared to CNY 244.30 million in the same period last year, reflecting an increase of about 2.8%[22]. - The total comprehensive income for Q1 2019 was CNY 211.69 million, up from CNY 205.38 million in the previous year, indicating a growth of approximately 3.2%[23]. - The net profit for Q1 2019 reached CNY 211.01 million, compared to CNY 205.99 million in Q1 2018, reflecting a year-over-year increase of about 2.0%[22]. Cash Flow - The net cash flow from operating activities significantly increased by 530.08%, reaching ¥76,206,590.42 compared to ¥12,094,762.53 in the previous year[3]. - Cash flow from operating activities for Q1 2019 was CNY 713.80 million, compared to CNY 593.55 million in Q1 2018, representing an increase of about 20.3%[27]. - Total cash inflow from operating activities reached 726,022,369.93 CNY, compared to 602,747,444.02 CNY in the same period last year, indicating an increase of approximately 20.5%[28]. - Cash outflow from operating activities totaled 649,815,779.51 CNY, up from 590,652,681.49 CNY, representing an increase of about 10%[28]. - The net cash flow from investment activities was -723,810,507.24 CNY, an improvement from -923,484,508.58 CNY year-over-year[29]. - The cash and cash equivalents at the end of the period were 1,844,380,147.93 CNY, down from 2,187,139,204.48 CNY, reflecting a decrease of about 15.7%[29]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,345,864,760.65, a 2.91% increase from ¥5,194,882,257.35 at the end of the previous year[3]. - Total liabilities decreased to approximately ¥1.05 billion from ¥1.11 billion at the end of the previous year[15]. - Total assets reached approximately ¥5.35 billion, up from ¥5.19 billion at the end of the previous year[14]. - Total current assets were CNY 1,335,894,138.16, with cash and cash equivalents at CNY 1,059,726,925.70[35]. - Total liabilities reached CNY 1,110,927,768.65, with current liabilities at CNY 619,968,077.61[34]. Shareholder Information - The top ten shareholders held a combined 99.87% of the total shares, with Chengdu Kanghong Technology Industry (Group) Co., Ltd. holding 33.35%[6]. - The total equity attributable to shareholders of the parent company reached CNY 4,296,053,944.07, up from CNY 4,083,954,488.70, marking an increase of approximately 5.2%[18]. - Shareholders' equity totaled CNY 4,083,954,488.70, with undistributed profits of CNY 2,526,888,621.06[34]. Research and Development - Research and development expenses rose by 43.09% year-on-year, attributed to increased R&D investment[10]. - Research and development expenses increased to CNY 46,433,584.24 in Q1 2019, compared to CNY 32,449,971.93 in the previous year, reflecting a significant increase of approximately 43%[21]. - Research and development expenses increased to CNY 23.74 million in Q1 2019, up from CNY 13.83 million in the same period last year, marking a significant increase of approximately 71.8%[24]. Other Financial Metrics - The weighted average return on net assets was 5.04%, a decrease of 0.61% from the previous year[3]. - The basic earnings per share remained stable at ¥0.31, while diluted earnings per share increased by 3.33% to ¥0.31[3]. - The company reported a significant decrease of 80.32% in financial expenses year-on-year, mainly due to exchange rate fluctuations[10]. - The company incurred income tax expenses of CNY 40.02 million in Q1 2019, up from CNY 38.32 million in Q1 2018, indicating an increase of approximately 4.4%[22]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[21].

Financial Performance - The company's operating revenue for 2018 was ¥2,917,445,131.66, representing a 4.70% increase compared to ¥2,786,497,000.62 in 2017[11]. - The net profit attributable to shareholders for 2018 was ¥694,943,801.74, an increase of 7.88% from ¥644,199,027.01 in 2017[11]. - The company reported a basic earnings per share of ¥1.04 for 2018, up 8.33% from ¥0.96 in 2017[11]. - The revenue from chemical drugs was CNY 1,169,995,125.14, showing an increase of 8.02% year-on-year[31]. - The revenue from biological products reached CNY 882,090,768.08, with a significant growth of 42.79% compared to the previous year[31]. - The company’s traditional Chinese medicine revenue decreased by 20.40% to CNY 863,378,989.41[31]. - The total revenue from the pharmaceutical industry amounted to 227,818,268.62 CNY in 2018, a decrease of 15.17% from 268,546,852.93 CNY in 2017[35]. - The company achieved a total operating revenue of CNY 2,917,445,131.66 in 2018, representing a year-on-year growth of 4.70%[31]. - The company reported a total revenue of 1.5 billion CNY for the year 2018, representing a year-over-year growth of 20%[86]. - The net profit for 2018 was 300 million CNY, an increase of 15% compared to the previous year[86]. Dividend Distribution - The company reported a total profit distribution plan based on 673,536,680 shares, proposing a cash dividend of 2.80 RMB per 10 shares (tax included) and a capital reserve increase of 3 shares per 10 shares[1]. - The company plans to distribute a cash dividend of CNY 2.80 per 10 shares for the 2018 fiscal year, totaling CNY 188,590,270.40[81]. - The cash dividend for 2017 was CNY 2.80 per 10 shares, amounting to CNY 188,778,807.56, which represented 29.30% of the net profit attributable to shareholders[80]. - The cash dividend for 2016 was CNY 1.50 per 10 shares, totaling CNY 101,243,109.00, accounting for 20.38% of the net profit attributable to shareholders[80]. - The total distributable profit for 2018 was CNY 694,943,801.74, with the cash dividend representing 48.28% of this amount[81]. - The total cash dividend for 2018, including other methods, is CNY 188,590,270.40, which is 27.14% of the net profit attributable to shareholders[80]. - The company has maintained a consistent cash dividend policy over the past three years, with clear standards and procedures in place[81]. Research and Development - The company has established four key technologies in drug development, including large molecule protein drug industrialization technology and standardized quality control technology for traditional Chinese medicine[18]. - The company’s R&D investment has increased, with a focus on high-quality new products in ophthalmology, neurology, and oncology[24]. - The company has 57 ongoing research projects, including a new drug for diabetic macular edema that has completed clinical trials and is under review for market approval[41]. - The total amount of R&D investment was 348,861,949.84 CNY, representing 11.96% of the company's revenue in 2018, a decrease from 12.56% in 2017[43]. - Research and development expenses increased by 20.02% year-on-year, totaling 230,365,772.13 CNY in 2018 compared to 191,933,002.81 CNY in 2017[40]. - The company obtained 29 authorized patents during the reporting period, bringing the total to 203, including 99 foreign patents[29]. - The company has established a comprehensive technical system for new drug research, including a New Drug Research Institute and a Medical Research Center[69]. Market Expansion and Strategy - The company aims to enhance its market presence through continuous innovation and collaboration in the pharmaceutical sector[18]. - The company is expanding its market presence in response to intensified competition from multinational pharmaceutical companies entering the domestic market[68]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2020[86]. - The company is focused on expanding its marketing service network, although it faced challenges due to local purchase restrictions and fluctuations in housing prices[55]. - The sales strategy will be market-driven, with a focus on rapid market capture and refined marketing strategies, utilizing data analysis for better market insights[71]. - The company is exploring partnerships with international firms to enhance its global distribution network[186]. Risks and Challenges - The company faces risks including declining sales prices, challenges in drug development, implementation of fundraising projects, and talent shortages[1]. - The company faces risks including potential sales price declines due to healthcare reforms and increased competition in the pharmaceutical market[74]. - There is a significant investment in drug R&D, which carries risks of uncertainty and potential failure due to the lengthy and costly development process[74]. - The company faced delays in project progress due to design optimization and market conditions affecting the expansion of traditional Chinese medicine production lines[55]. Social Responsibility - The company actively participated in social responsibility initiatives, donating 44.23 million to various charitable causes in 2018[123]. - The company has established the "Langshijie Muguangming" fund to support medical precision poverty alleviation, benefiting impoverished areas with free medical services[122]. - The company organized 205 public health activities, including free health consultations and lectures, to promote community health awareness[123]. - The company has committed to integrating social responsibility into its business strategy, with a dedicated team led by the chairman[120]. - The company has provided free medical products worth over 200 million to impoverished patients since the establishment of its public welfare fund in 2014[122]. Environmental Compliance - The company is listed as a key pollutant discharge unit, with specific emissions monitored and reported[127]. - The company maintained compliance with environmental discharge standards, with no instances of exceeding pollutant limits reported[129]. - The company has implemented a pollution liability insurance policy as part of its environmental protection measures[151]. - The company has engaged in community environmental awareness activities, such as the "Kanghong Pharmaceutical and You Build a Happy Community" campaign[150]. Corporate Governance - The company has established a performance evaluation system linking remuneration to company performance and individual performance[191]. - The company operates independently from its controlling shareholder in terms of business, personnel, assets, institutions, and finance[199]. - The company has established a complete independent business structure and operates its own supply, production, and sales systems[199]. - The company has not reported any changes in its actual controller during the reporting period[173].

成都康弘药业集团股份有限公司 2018 年第三季度报告全文 成都康弘药业集团股份有限公司 2018 年第三季度报告 2018-075 2018 年 10 月 1 成都康弘药业集团股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证季度报告中财务报表的真实、准确、完整。 2 成都康弘药业集团股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,950,080,379.05 | 4,586,159,245.38 | | 7.94% | | 归属于上市公司股东的净 ...

成都康弘药业集团股份有限公司 2018 年半年度报告全文 成都康弘药业集团股份有限公司 2018 年半年度报告 2018-060 2018 年 08 月 1 成都康弘药业集团股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证本半年度报告中财务报告的真实、准确、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 2018 | 年半年度报告 2 | | --- | --- | | 第一节 | 重要提示、释义 2 | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 公司业务概要 8 | | 第四节 | 经营情况讨论与分析 26 | | 第五节 | 重要事项 26 | | 第六节 | 股份变动及股东情况 43 | | 第七节 | 优先股相关情况 55 | | 第八节 | 董事、监事、高级管 ...

成都康弘药业集团股份有限公司 2017 年年度报告全文 成都康弘药业集团股份有限公司 2017 年年度报告 2018-018 2018 年 04 月 1 成都康弘药业集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1 、销售价格下降的风险 随着国家基本医疗保险制度改革的深入、相关 政策法规的调整或出台，我国药品降价的趋势仍将持续，尤其是随着卫生部门 药品网上招标采购、医疗保险对药费支付设置限制标准等政策的推进，公司产 品的销售价格可能会因此而降低；同时，医药产品市场竞争的进一步加剧，医 院药品招投标采购方式的进一步推广和变革，也可能导致本公司产品价格的下 降。 2、药品研发风险 公司基于未来发展所需，每年都必须投入大量资金 用于药品的研发。一种新药从实验研究、临 ...

成都康弘药业集团股份有限公司 2018 年第一季度报告正文 证券代码：002773 证券简称：康弘药业 公告编号：2018-024 成都康弘药业集团股份有限公司 2018 年第一季度报告正文 1 成都康弘药业集团股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证季度报告中财务报表的真实、准确、完整。 2 所有董事均已出席了审议本次季报的董事会会议。 √ 适用 □ 不适用 成都康弘药业集团股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 699,991,074.72 | 642,039,416.94 | 9.03% | ...

成都康弘药业集团股份有限公司 2017 年年度报告全文 成都康弘药业集团股份有限公司 2017 年年度报告 2018-018 1 成都康弘药业集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1 、销售价格下降的风险 随着国家基本医疗保险制度改革的深入、相关 政策法规的调整或出台，我国药品降价的趋势仍将持续，尤其是随着卫生部门 药品网上招标采购、医疗保险对药费支付设置限制标准等政策的推进，公司产 品的销售价格可能会因此而降低；同时，医药产品市场竞争的进一步加剧，医 院药品招投标采购方式的进一步推广和变革，也可能导致本公司产品价格的下 降。 2、药品研发风险 公司基于未来发展所需，每年都必须投入大量资金 用于药品的研发。一种新药从实验研究、临床试验、获得新药证书到正 ...

所有董事均已出席了审议本次季报的董事会会议。 成都康弘药业集团股份有限公司 2017 年第三季度报告全文 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明:保证季度报告中财务报表的真实、准确、完整。 成都康弘药业集团股份有限公司 2017 年第三季度报告 2017 年 10 月 l 成都康弘药业集团股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 2 成都康弘药业集团股份有限公司 2017年第三季度报告全文 | 项目 | 年初至报告期期末全额 | 说明 | | --- | --- | --- | | 非流动资产处置损益(包括已计提资产减值准备的冲销部分) | | -49,220.87 系固定资报废处置损失 | | 计入当期损益的政府补助(与企业业务密切相关,按照国家统 | 15,791,175.68 | 系当期收到及从递延收益转入 | | 标准定额或定量享受的政府补助除外) | | 的政府补助 | | 除上述 ...

成都康弘药业集团股份有限公司 2017 年半年度报告全文 () was and 成都康弘药业集团股份有限公司 2017 年半年度报告 2017年08月 l 成都康弘药业集团股份有限公司 2017年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和 连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能存在销售价格下降、药品研发、募投项目实施、人才缺乏等风险, 有关风险因素内容已在本报告中第四节"经营情况讨论与分析"第十部分"公司 面临的风险和应对措施"部分予以描述。敬请广大投资者注意投资风险。 公司计划不派发现金红利,不送红股,不以公积金转增股本。 2 成都康弘药业集团股份有限公司 2017年半年度报告全文 | | | | 2017 半年度报告 . | | --- | | 第一节 重要提示、释义 | | 第二节 公司简介和主要财务指 ...

成都康弘药业集团股份有限公司 2017 年第一季度报告正文 证券代码：002773 证券简称：康弘药业 公告编号：2017-027 成都康弘药业集团股份有限公司 2017 年第一季度报告正文 1 成都康弘药业集团股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计主 管人员)何映梅声明：保证季度报告中财务报表的真实、准确、完整。 成都康弘药业集团股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 2 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 642,039,416.94 | 523,601,977.96 | 22.62 ...